A Full-Spectrum Generative Lead Discovery (FSGLD) pipeline via DRUG-GAN: A multiscale method for drug-like/target-specific compound library generation.
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: The generative pipeline produced candidates for experimental screening; the primary preprint reports one tested candidate with measured CB2 binding, while the journal version also reports HER4 work. This supports a narrow initial-hit result, not a validated therapeutic.
Technology: Journal Methods/Results and the Research Square v1 PDF establish the generative operation, screening workflow, nine-compound assay and limited CB2 binding result; preprint posted 2025-05-12.
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- Journal Methods/Results and the Research Square v1 PDF establish the generative operation, screening workflow, nine-compound assay and limited CB2 binding result; preprint posted 2025-05-12.
- Limitation / still unknown
- The evidence supports initial measured CB2 binding (and journal-version HER4 work), not a validated therapeutic, animal efficacy or human benefit.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pmc&id=PMC13715712
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.